Aegerion Pharmaceuticals
This sponsor has funded 2 studies across 16 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 5329 | Planned | Global Lomitapide (Juxtapid and Lojuxta) Pregnancy Exposure Registry (PER) | Yes | No |
| 7957 | Planned | Effects of Lomitapide on Carotid and Aortic Atherosclerosis in Patients Treated with Lomitapide in Usual Care (CAPTURE) | Yes | No |
PAS by Risk Management Plan (RMP) requirement
Aegerion Pharmaceuticals
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Aegerion Pharmaceuticals
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Aegerion Pharmaceuticals
16 Study countries specified are the following:
- Argentina
- Austria
- Brazil
- Canada
- Denmark
- France
- Germany
- Italy
- Netherlands
- Norway
- Poland
- Spain
- Sweden
- Taiwan
- United Kingdom
- United States